연구동향 분석

Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer

신현석 최주환 이진환 이승룡 2022년

논문상세정보
인용/피인용
' Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Histone deacetylase
  • Immune checkpoint inhibitor
  • Interleukin
  • Programmed cell death 1
  • Tumor microenvironment
  • histonedeacetylaseinhibitor
  • non-small cell lung carcinoma
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
129 0

0.0%

' Histone Deacetylase as a Valuable Predictive Biomarker and Therapeutic Target in Immunotherapy for Non-Small Cell Lung Cancer' 의 참고문헌

  • Trends in the global immuno-oncology landscape
    Tang J [2018]
  • Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen
    Lin KY [1996]
  • Targeting interleukin-6(IL-6)sensitizes anti-PD-L1 treatment in a colorectal cancer preclinical model
    Li J [2018]
  • Targeted cancer therapy : giving histone deacetylase inhibitors all they need to succeed
    Gryder BE [2012]
  • Synergistic enhancement of cancer therapy using HDAC inhibitors : opportunity for clinical trials
  • Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
    Knox T [2019]
  • Regulatory T cells in the tumor microenvironment and cancer progression : role and therapeutic targeting
    Chaudhary B [2016]
  • Pembrolizumab versus chemotherapy for PD-L1-positive nonsmall-cell lung cancer
    Reck M [2016]
  • PD-L1 biomarker testing for non-small cell lung cancer : truth or fiction?
    Grigg C [2016]
  • NF-kappaB, inflammation, immunity and cancer : coming of age
  • Myeloid-derived suppressor cells as a therapeutic target for cancer
    Law AM [2020]
  • Molecular and biochemical aspects of the PD-1 checkpoint pathway
  • Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment
    Spranger S [2016]
  • Immunosuppression associated with chronic inflammation in the tumor microenvironment
    Wang D [2015]
  • Immunoepigenetics combination therapies : an overview of the role of HDACs in cancer immunotherapy
    Banik D [2019]
  • Immune-related adverse events associated with immune checkpoint blockade
    Postow MA [2018]
  • IL-1 and IL-1 regulatory pathways in cancer progression and therapy
    Mantovani A [2018]
  • How cancers escape immune destruction and mechanisms of action for the new significantly active immune therapies : helping nonimmunologists decipher recent advances
  • Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes : role of microtubules
    Carta S [2006]
  • Histone deacetylase inhibition sensitizes PD1 blockade-resistant B-cell lymphomas
    Wang X [2019]
  • HDACs and HDAC inhibitors in cancer deve-lopment and therapy
    Li Y [2016]
  • HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics
    Laino AS [2019]
  • HDAC3 inhibition upregulates PD-L1 expression in B-cell lymphomas and augments the efficacy of anti-PD-L1 therapy
    Deng S [2019]
  • HDAC expression and clinical prognosis in human malignancies
    Weichert W [2009]
  • HDAC Inhibitors as epigenetic regulators of the immune system : impacts on cancer therapy and inflammatory diseases
    Hull EE [2016]
  • Emerging strategies for combination checkpoint modulators in cancer immunotherapy
    Popovic A [2018]
  • Coordinated regulation of myeloid cells by tumours
  • Combining DNMT and HDAC6 inhibitors increases anti-tumor immune signaling and decreases tumor burden in ovarian cancer
    Moufarrij S [2020]
  • Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling
    Bretz NP [2013]
  • A review of canakinumab and its therapeutic potential for non-small cell lung cancer
    Schenk KM [2019]